Britain's health regulator said on Friday it has approved Moderna's vaccine for respiratory syncytial virus in adults 60 ...

A study found that around 4 months after vaccination, people who received the RSV vaccine had a 79% reduction in their risk ...

The vaccine, manufactured by US pharmaceutical giant Moderna, was found to slash the risk of severe illness from respiratory ...

RESVIA® is Moderna's second approved product in the UK CAMBRIDGE, MA / ACCESS Newswire / February 28, 2025 / Moderna, Inc. (NASDAQ:MRNA) ...

The stocks in the Hong Kong pharmaceutical sector have recently shown an upward trend. As global capital flows positively ...

Robust immune responses were observed among healthy and high-risk younger adults who received the Ad26/protein RSV preF vaccine.

Emily and Joey Spadafore watched helplessly as their 3-month-old son, Benjamin, battled RSV for a week in the hospital.

Moderna (MRNA) announced that the Medicines and Healthcare products Regulatory Agency in the UK has granted marketing authorization for ...

Spring is just around the corner, but this year's flu season is still clinging on and causing misery for millions of people ...

In this piece, we include reporting tips, how vaccine side effects are tracked in the U.S., and what research shows about the ...

Expectant mums and elderly people who haven’t yet had their vaccination against the life-threatening RSV virus that is spreading in London ...

"The MHRA's authorization of our RSV vaccine is an important milestone for Moderna's efforts toward respiratory disease preparedness," said Stéphane Bancel, Chief Executive Officer of Moderna.